Fixed-dose combinations of renin-angiotensin blocking agents with calcium channel blockers or hydrochlorothiazide in the treatment of hypertension

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 11, 2009, Pages 1755-1767

  Bramlage, Peter ^a  

^a Institute for Cardiovascular Pharmacology and Epidemiology   (Germany)

Author keywords

ACE inhibitors; Amlodipine; Angiotensin receptor blockers; Combination treatment; First line treatment

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; AMLODIPINE PLUS VALSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN PLUS AMLODIPINE; CAPTOPRIL PLUS HYDROCHLOROTHIAZIDE; DELAPRIL PLUS MANIDIPINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; INDAPAMIDE PLUS PERINDOPRIL; OLMESARTAN PLUS HYDROCHLOROTHIAZIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RAMIPRIL; TELMISARTAN; THIAZIDE DIURETIC AGENT; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ANGIONEUROTIC EDEMA; BLOOD PRESSURE MONITORING; DIABETES MELLITUS; DISEASE DURATION; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; EDEMA; FIBRINOLYSIS; HEADACHE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LOW DRUG DOSE; METABOLIC DISORDER; MONOTHERAPY; MORBIDITY; MORTALITY; ORTHOSTATIC BLOOD PRESSURE; PERIPHERAL EDEMA; PRACTICE GUIDELINE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CONTROLLED CLINICAL TRIALS AS TOPIC; DRUG COMBINATIONS; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; PRACTICE GUIDELINES AS TOPIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 68149162414     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903036103     Document Type: Review

References (42)

1. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003;289:2363-2369 • Comprehensive comparison of hypertension prevalence in a number of western countries.
2. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-1913 (Pubitemid 35472129)
3. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001;345:1291-1297 (Pubitemid 34940740)
4. Kearney PM, Whelton M, Reynolds K, et al. Worldwide prevalence of hypertension: a systematic review. J Hypertens 2004;22:11-19 (Pubitemid 38293521)
5. Sharma AM, Wittchen HU, Kirch W, et al. High prevalence and poor control of hypertension in primary care: cross-sectional study. J Hypertens 2004;22:479-486 (Pubitemid 38368480)
6. Bramlage P, Pittrow D, Wittchen H, et al. High body mass index is associated with an increased prevalence and lack of control of hypertension. Am J Hypertens 2004;17:904-910
7. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860 • First report on renoprotection by angiotensin receptor blockers.
8. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-2031 (Pubitemid 38781102)
9. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-1187 (Pubitemid 46924065)
10. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-2428 •• The only comparison of fixed dose combinations with respect to morbidity and mortality available so far.
11. Neutel JM, Franklin SS, Oparil S, et al. Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension. J Clin Hypertens (Greenwich) 2006;8:850-7;quiz 8-9
12. Li Y, Liu G, Jiang B, et al. A comparison of initial treatment with losartan/HCTZ versus losartan monotherapy in chinese patients with mild to moderate essential hypertension. Int J Clin Pract 2003;57:673-677 (Pubitemid 37428202)
13. Pittrow D, Kirch W, Bramlage P, et al. Patterns of antihypertensive drug utilization in primary care. Eur J Clin Pharmacol 2004;60:135-142 (Pubitemid 38626444)
14. Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003;326:1427-1431 •• The largest meta-analysis so far of antihypertensive efficacy of drugs.
15. Jamerson KA, Bakris GL, Wun CC, et al. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am J Hypertens 2004;17:793-801
16. Collins R, Peto R, Macmahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-838
17. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-1535 (Pubitemid 37410190)
18. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887-1898 (Pubitemid 351620109)
19. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002;288:2981-2997 (Pubitemid 35471160)
20. Roca-Cusachs A, Schmieder RE, Triposkiadis F, et al. Efficacy of manidipine/delapril versus losartan/ hydrochlorothiazide fixed combinations in patients with hypertension and diabetes. J Hypertens 2008;26:813-818 (Pubitemid 351354931)
21. Fogari R, Zoppi A, Mugellini A, et al. Efficacy and safety of two treatment combinations of hypertension in very elderly patients. Arch Gerontol Geriatr 2009;48:401-405
22. Poldermans D, Glazes R, Kargiannis S, et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther 2007;29:279-289 (Pubitemid 46661857)
23. Shimosawa T, Gohchi K, Yatomi Y, et al. Effectiveness of add-on low-dose diuretics in combination therapy for hypertension: losartan/hydrochlorothiazide vs. candesartan/amlodipine. Hypertens Res 2007;30:831-837 (Pubitemid 47578245)
24. Fogari R, Derosa G, Zoppi A, et al. Effects of manidipine/delapril versus olmesartan/ hydrochlorothiazide combination therapy in elderly hypertensive patients with type 2 diabetes mellitus. Hypertens Res 2008;31:43-50 (Pubitemid 351325614)
25. Mugellini A, Preti P, Zoppi A, et al. Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus. J Hum Hypertens 2004;18:687-691 (Pubitemid 39369188)
26. Matchar DB, Mccrory DC, Orlando LA, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008;148:16-29
27. Reboldi G, Angeli F, Cavallini C, et al. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens 2008;26:1282-1289
28. Plosker GL, Robinson DM. Amlodipine/ Valsartan: fixed-dose combination in hypertension. Drugs 2008;68:373-381
29. Chrysant SG, Melino M, Karki S, et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008;30:587-604 (Pubitemid 351680489)
30. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004;363:2049-2051 (Pubitemid 38781107)
31. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906 (Pubitemid 41265663)
32. Laurent S. Clinical benefit of very-low-dose perindopril-indapamide combination in hypertension. J Hypertens Suppl 2001;19:S9-14 (Pubitemid 33753143)
33. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-878 (Pubitemid 34940826)
34. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003 (Pubitemid 34286536)
35. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003;289:2534-2544 •• Extensive network meta-analysis of antihypertensive drugs. (Pubitemid 37430155)
36. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004;351:1952-1961 (Pubitemid 39447136)
37. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-752 (Pubitemid 27122456)
38. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-1587 (Pubitemid 30240502)
39. The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-1559 •• The first comparison of angiotensin receptor blockers and angiotensin converting enzyme inhibitor in nonhypertensive patients.
40. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002;360:752-760 (Pubitemid 35247704)
41. Pfeffer MA, Mcmurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-1906 (Pubitemid 37409706)
42. Mcmurray J, Solomon S, Pieper K, et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol 2006;47:726-733 (Pubitemid 43245597)